$15.34
1.92% yesterday
Nasdaq, Jun 13, 10:17 pm CET
ISIN
US24661P5008
Symbol
DCTH

Delcath Systems Inc Stock price

$15.34
+0.05 0.33% 1M
+3.23 26.67% 6M
+3.30 27.41% YTD
+7.92 106.74% 1Y
+6.90 81.75% 5Y
-2,077,599,984.66 100.00% 10Y
-97,215,999,984.66 100.00% 20Y
Nasdaq, Closing price Fri, Jun 13 2025
-0.30 1.92%
ISIN
US24661P5008
Symbol
DCTH
Sector

Key metrics

Market capitalization $534.23m
Enterprise Value $475.33m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 8.83
P/S ratio (TTM) P/S ratio 9.92
P/B ratio (TTM) P/B ratio 6.39
Revenue growth (TTM) Revenue growth 1,068.11%
Revenue (TTM) Revenue $53.85m
EBIT (operating result TTM) EBIT $-1.49m
Free Cash Flow (TTM) Free Cash Flow $-7.58m
Cash position $58.90m
EPS (TTM) EPS $-0.35
P/E forward 255.67
P/S forward 5.60
EV/Sales forward 4.98
Short interest 2.21%
Show more

Is Delcath Systems Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,847 stocks worldwide.

Delcath Systems Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Delcath Systems Inc forecast:

7x Buy
100%

Analyst Opinions

7 Analysts have issued a Delcath Systems Inc forecast:

Buy
100%

Financial data from Delcath Systems Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
54 54
1,068% 1,068%
100%
- Direct Costs 8.13 8.13
502% 502%
15%
46 46
1,307% 1,307%
85%
- Selling and Administrative Expenses 32 32
20% 20%
59%
- Research and Development Expense 15 15
9% 9%
28%
-1.34 -1.34
97% 97%
-2%
- Depreciation and Amortization 0.15 0.15
15% 15%
0%
EBIT (Operating Income) EBIT -1.49 -1.49
96% 96%
-3%
Net Profit -14 -14
71% 71%
-26%

In millions USD.

Don't miss a Thing! We will send you all news about Delcath Systems Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Delcath Systems Inc Stock News

Neutral
Seeking Alpha
2 days ago
Delcath's HEPZATO shows rapid sales growth and high pricing, but its efficacy is only moderately better than alternatives and not curative. The addressable market is small, treatment is complex, and future competition from Replimune or Ideaya could threaten long-term prospects and valuation multiples. Financials are solid with no debt, recent profitability, and reasonable stock-based compensati...
Neutral
Business Wire
23 days ago
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced full year 2025 financial guidance and its intention to enter into a Medicaid National Drug Rebate Agreement (NDRA) to expand patient access. 2025 Full Year Financial Guidance The...
Positive
Seeking Alpha
27 days ago
Delcath's commercial execution post-HEPZATO launch has driven impressive revenue growth, positive cash flow, and a shift from speculative to established biotech. Q1 earnings beat expectations with 530% revenue growth, positive EBITDA, and net income, validating the company's scalability and operational progress. Growth drivers include expanding U.S. treatment centers, pipeline development for n...
More Delcath Systems Inc News

Company Profile

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers. The company's lead product candidate is the melphalan hydrochloride for injection for use with the Delcath hepatic delivery system to administer high-dose chemotherapy to the liver. Its Phase III clinical trial products include FOCUS Trial for the patients with hepatic dominant ocular melanoma; and ALIGN Trial for intrahepatic cholangiocarcinoma. The company also offers melphalan hydrochloride under the Delcath Hepatic CHEMOSAT Delivery System for Melphalan name in Europe. The company was founded in 1988 and is headquartered in New York, New York.

Head office United States
CEO Gerard Michel
Employees 96
Founded 1988
Website delcath.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today